Debio 4126

Phase 3

DDebiopharm International SA

Debio 4126 is one of 7 therapeutic programs targeting Acromegaly. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[2][1]

Indication

AcromegalyRecruiting

AcromegalyPhase 3

Recruiting

Competition

Competitive Landscape

11 competitors in Acromegaly

#DrugCompanyPhaseTrials

Sandostatin

Sun Pharma

Approved

7 2

Lanreotide Acetate

AAlbireo, an Ipsen Company

Approved

5 3

Debio 4126

DDebiopharm International SA

Phase 3

1 4

Dostinex

MAR002

1 6

Genotropin

Pfizer

Preclinical

1 7

Sandostatin

CSPC ZhongQi Pharmaceutical Technology Co., Ltd.

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q1 2029

Phase 3Recruiting

Acromegaly

NCT06930625

Clinical

Trials by Indication[1]

Acromegaly1 trial

A Phase 3 Randomized 3-arm Trial (Double-blind Debio 4126, Placebo Control, and Open-label Debio 4126), to Assess the Efficacy and Safety of Debio 4126, a 12-week Octreotide Formulation, in Patients With Acromegaly Previously Treated With Somatostatin Analogs

Recruiting·DDebiopharm International SA·Phase 3·NCT06930625·119 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Debio 4126. U.S. National Library of Medicine, National Institutes of Health.
[2]
Open Targets Platform — Drug–disease associations for Debio 4126. EMBL-EBI & Wellcome Sanger Institute.
[3]
SEC EDGAR — Debiopharm International SA company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Highest Phase: Phase 3[1]
Company: DDebiopharm International SA

Debio 4126

Status by Indication[2][1]

Competitive Landscape

Expected Milestones

Q1 2029

Trials by Indication[1]

Acromegaly1 trial

References

Drug Info

Quick Facts

Related News